Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 48
Filter
1.
Reumatol Clin ; 8(5): 284-6, 2012.
Article in English | MEDLINE | ID: mdl-22377450

ABSTRACT

The intravesical instilation of bacillus Calmette-Guérin (BCG) is a widely used and efficacious procedure for treatment of intermediate to high-grade superficial bladder cancer. The occurrence of osteoarticular side effects is infrequent compared to the number of administrated doses, and reactive arthritis is included within these effects. We present the case of a 54 years old HLA-27 (+) male, who developed reactive arthritis featuring asymmetric olygoarthritis and dactylitis after the second intravesical BCG instillation, which was resolved with administration of Etoricoxib and Isoniazid.


Subject(s)
Arthritis, Reactive/etiology , BCG Vaccine/adverse effects , Administration, Intravesical , BCG Vaccine/therapeutic use , Carcinoma, Transitional Cell/complications , Carcinoma, Transitional Cell/surgery , Carcinoma, Transitional Cell/therapy , Combined Modality Therapy , Genetic Predisposition to Disease , HLA-B27 Antigen/analysis , HLA-B7 Antigen/analysis , Humans , Immunotherapy , Instillation, Drug , Male , Middle Aged , Urinary Bladder Neoplasms/complications , Urinary Bladder Neoplasms/surgery , Urinary Bladder Neoplasms/therapy
3.
Eur J Immunol ; 33(10): 2744-54, 2003 Oct.
Article in English | MEDLINE | ID: mdl-14515258

ABSTRACT

We compared in an inducible expression system the individual effect of US2, US6 and US11 human cytomegalovirus (HCMV) proteins on HLA-E and HLA class Ia surface expression, assessing in parallel their influence on target susceptibility to NK cell clones. To this end, the RPMI 8866 B lymphoma cell line (HLA-A2, HLA-A3, HLA-B7, HLA-Cw7, HLA-E(R), HLA-E(G)) was stably cotransfected with the ecdysone receptor, together with the US sequences under the control of an ecdysone-inducible promoter. Biosynthesis of viral proteins was turned on by incubating transfectants with Ponasterone A. US6 down-regulated expression of all class I molecules, hampering target resistance to NK cell clones controlled by the CD94/NKG2A, KIR2DL2 and/or CD85j (ILT2 or LIR-1) inhibitory receptors. By contrast, US11 reduced the surface levels of class Ia molecules but preserved HLA-E; this rendered US11(+) cells sensitive to NK clones under the control of KIR2DL2 and/or CD85j, while their resistance to CD94/NKG2A(+)KIR2DL2(-) effector cells was maintained. US2 preserved as well HLA-E expression but selectively targeted class Ia molecules; in fact, HLA-A and HLA-C allotypes were down-modulated whereas HLA-B7 remained unaltered. US2(+) targets became sensitive to KIR2DL2(+) cells but remained resistant to CD94/NKG2A(+)CD85j(+) NK clones. The differential effects of US proteins on HLA class Ia and HLA-E likely reflect the evolutionary adaptation of HCMV to counteract NK-mediated surveillance.


Subject(s)
Cytotoxicity, Immunologic , HLA Antigens/analysis , Histocompatibility Antigens Class I/analysis , Killer Cells, Natural/immunology , Membrane Glycoproteins/physiology , RNA-Binding Proteins/physiology , Viral Proteins/physiology , HLA Antigens/genetics , HLA-A2 Antigen/analysis , HLA-A3 Antigen/analysis , HLA-B7 Antigen/analysis , HLA-C Antigens/analysis , Histocompatibility Antigens Class I/genetics , Humans , Viral Envelope Proteins , HLA-E Antigens
4.
J Oral Maxillofac Surg ; 60(7): 778-83, 2002 Jul.
Article in English | MEDLINE | ID: mdl-12089692

ABSTRACT

PURPOSE: Spondyloarthropathy includes the subcategory of reactive arthritis (ReA). Spondyloarthropathies are commonly associated with certain human leukocyte antigen (HLA) alleles. Because we identified bacteria associated with ReA within the temporomandibular joint (TMJ), we now evaluate the frequency of HLA alleles in patients with TMJ pathology. PATIENTS AND METHODS: HLA typing of 129 patients (121 females and 8 males) performed by standard microcytotoxicity technique. Thirty patients had only class I (HLA-A and -B loci) evaluated. Ninety-nine patients had both class I and class II (HLA-DR loci) evaluated. Identification of alleles at the C locus was not performed. The antigenic frequency in the study group was compared to US white control subjects using a 2-tailed Fisher's exact test with a Bonferroni multiple comparison adjustment. RESULTS: The following class I HLA alleles, -A1 (32%), -A2 (50%), -A3 (33%), -B7 (23%), -B14 (14%), -B35 (20%), and -B44 (36%), including the B7 cross-reactive group (CREG) (49%) and class II alleles -DR1 (25%) and -DR4 (34%), were found to have an increased frequency in our patient group. CONCLUSIONS: Our study shows an increased frequency of several alleles that have been previously associated with arthropathy, and the alleles of the B7 CREG, in patients with TMJ pathology. Patients with these alleles may have an increased risk for the development of internal derangement of the TMJ as a consequence of the bacterial/infectious agents and host interactions with the subsequent cytokine/inflammatory response being influenced by their HLA phenotype.


Subject(s)
HLA Antigens/analysis , Joint Dislocations/immunology , Temporomandibular Joint Disc/immunology , Alleles , Arthritis, Reactive/immunology , Case-Control Studies , Chromosome Mapping , Cross Reactions , Disease Susceptibility , Female , HLA-A Antigens/analysis , HLA-A1 Antigen/analysis , HLA-A2 Antigen/analysis , HLA-A3 Antigen/analysis , HLA-B Antigens/analysis , HLA-B14 Antigen , HLA-B35 Antigen/analysis , HLA-B44 Antigen , HLA-B7 Antigen/analysis , HLA-DR Antigens/analysis , HLA-DR1 Antigen/analysis , HLA-DR4 Antigen/analysis , Humans , Likelihood Functions , Male , Prohibitins , Statistics as Topic , Temporomandibular Joint Disorders/immunology
5.
Proc Natl Acad Sci U S A ; 99(7): 4550-5, 2002 Apr 02.
Article in English | MEDLINE | ID: mdl-11917131

ABSTRACT

Lymphoblastoid cell lines, generated by immortalization of normal B cells by Epstein-Barr virus (EBV) in vitro, have strong antigen-presenting capacity, are sensitive to EBV-specific cytotoxic T cells, and are highly allostimulatory in mixed lymphocyte culture. By contrast, EBV-positive Burkitt lymphoma (BL) cells are poor antigen presenters, are not recognized by EBV-specific cytotoxic T cells, and are poorly allostimulatory, which raises the question of whether immunological pressure exerted during BL pathogenesis in vivo has selected for a 'nonimmunogenic' tumor phenotype. The present work addresses this question by examining the immunogenicity/antigenicity of cell lines, generated by conversion of a conditionally immortalized lymphoblastoid cell line to permanent growth independent of EBV-latent proteins by introduction of a constitutively active or tetracycline-regulated c-myc gene (A1 and P493-6 cells, respectively). Compared with its parental lymphoblastoid cell line, A1 cells showed many of the features of the nonimmunogenic BL phenotype, namely poor allostimulatory activity, poor antigen-presenting function associated with impaired proteasomal activity, down-regulation of peptide transporter, reduced HLA class I expression, and an inability to present endogenously expressed EBV-latent proteins to cytotoxic T cells. P493-6 cells, when grown in the presence of estrogen with the exogenous c-myc gene switched off, were strongly immunogenic. The cells had lost their immunogenic potential, however, when grown on a c-myc-driven proliferation program in the absence of estrogen. Deregulation of c-myc, a step central to the development of uncontrolled BL cell growth in vivo, can thus impose a nonimmunogenic phenotype on proliferating human B cells in the absence of any immune pressure.


Subject(s)
B-Lymphocytes/immunology , Herpesvirus 4, Human/immunology , Proto-Oncogene Proteins c-myc/physiology , Antigen Presentation , B-Lymphocytes/virology , Epstein-Barr Virus Nuclear Antigens/physiology , Genetic Vectors , HLA-A Antigens/analysis , HLA-A11 Antigen , HLA-B7 Antigen/analysis , Humans , Lymphocyte Activation , Lymphocyte Culture Test, Mixed , Phenotype , T-Lymphocytes, Cytotoxic/immunology , Vaccinia virus/genetics , Viral Proteins
6.
J Virol ; 75(14): 6279-91, 2001 Jul.
Article in English | MEDLINE | ID: mdl-11413294

ABSTRACT

Cytotoxic T lymphocytes (CTL) target multiple epitopes in human immunodeficiency virus (HIV)-infected persons, and are thought to influence the viral set point. The extent to which HLA class I allele expression predicts the epitopes targeted has not been determined, nor have the relative contributions of responses restricted by different class I alleles within a given individual. In this study, we performed a detailed analysis of the CTL response to optimally defined CTL epitopes restricted by HLA class I A and B alleles in individuals who coexpressed HLA A2, A3, and B7. The eight HIV-1-infected subjects studied included two subjects with acute HIV infection, five subjects with chronic HIV infection, and one long-term nonprogressor. Responses were heterogeneous with respect to breadth and magnitude of CTL responses in individuals of the same HLA type. Of the 27 tested epitopes that are presented by A2, A3, and B7, 25 were targeted by at least one person. However, there was wide variation in the number of epitopes targeted, ranging from 2 to 17. The A2-restricted CTL response, which has been most extensively studied in infected persons, was found to be narrowly directed in most individuals, and in no cases was it the dominant contributor to the total HIV-1-specific CTL response. These results indicate that HLA type alone does not predict CTL responses and that numerous potential epitopes may not be targeted by CTL in a given individual. These data also provide a rationale for boosting both the breadth and the magnitude of HIV-1-specific CTL responses by immunotherapy in persons with chronic HIV-1 infection.


Subject(s)
Epitopes, T-Lymphocyte/immunology , HIV Infections/immunology , HIV-1 , Histocompatibility Antigens Class I/immunology , T-Lymphocytes, Cytotoxic/immunology , Alleles , Chronic Disease , Epitopes, T-Lymphocyte/genetics , HIV Infections/virology , HLA-A1 Antigen/analysis , HLA-A2 Antigen/analysis , HLA-B7 Antigen/analysis , Humans
7.
Kidney Int ; 57(2): 476-86, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10652024

ABSTRACT

BACKGROUND: To assess the role of human peritoneal mesothelial cells (HPMCs) in the generation of an immune response during peritonitis, we tested their ability to activate T-cells by antigen presentation (AP) and by the secretion of interleukin-15 (IL-15). IL-15 is a potent leukocyte activator that stimulates the proliferation of CD4+, CD8+, and B and natural killer (NK) cells. METHODS: HPMCs and mononuclear cells were derived from six volunteer patients who underwent elective abdominal surgery. Flow cytometry was used to analyze human lymphocyte antigen-DR (HLA-DR), intercellular adhesion molecule-1 (ICAM-1), and B7 molecules on HPMCs. Affinity-purified CD4 cells were used for AP assays. We used a specific enzyme-linked immunosorbent assay to detect interferon-gamma (IFN-gamma), IL-2, and IL-15 protein and reverse transcription-polymerase chain reaction for mRNA analysis. RESULTS: HPMCs expressed HLA-DR molecules following IFN-gamma treatment. ICAM-1 molecules were expressed at high levels, and B7-1 and B7-2 molecules could not be detected. The accessory function of HPMCs was assayed by T-cell stimulation using anti-CD3 antibodies (OKT3). HPMCs were essential for a significant OKT3-induced T-cell proliferation. Anti-ICAM-1 antibodies blocked OKT3-induced proliferation. HPMCs served as effective antigen-presenting cells when Tetanus toxoid (TT) or Staphylococcus aureus-alpha-toxin were used as antigens. IFN-gamma, IL-2, and IL-15 accumulated during AP reactions. We found that IL-15 is produced by HPMCs, and IFN-gamma up-regulated its mRNA levels and protein secretion in a dose-dependent manner. We also detected IL-15 in the peritoneal effluent of patients undergoing continuous peritoneal dialysis treatment. In patients suffering from peritonitis, IL-15 levels were elevated (35.0 +/- 6.0 pg/mL, N = 10) as compared with noninfected patients (16.2 +/- 4.0 pg/mL, N = 7). CONCLUSIONS: HPMCs participate in the peritoneal immune response against invading pathogens by AP. For this process, ICAM-1 is the major accessory molecule. In addition, HPMCs may contribute to T-cell activation by secretion of IL-15.


Subject(s)
Antigen Presentation/immunology , CD4-Positive T-Lymphocytes/cytology , Epithelial Cells/immunology , Peritoneum/cytology , Adult , Bacterial Toxins/immunology , CD4-Positive T-Lymphocytes/immunology , Cell Division/immunology , Cells, Cultured , Epithelial Cells/cytology , Epithelial Cells/drug effects , Female , Flow Cytometry , Gene Expression/immunology , HLA-B7 Antigen/analysis , HLA-DR Antigens/analysis , Hemolysin Proteins/immunology , Humans , Immunosuppressive Agents/pharmacology , Intercellular Adhesion Molecule-1/analysis , Interferon-gamma/pharmacology , Interleukin-15/genetics , Interleukin-15/immunology , Interleukin-15/metabolism , Kidney Failure, Chronic/immunology , Kidney Failure, Chronic/therapy , Male , Middle Aged , Muromonab-CD3/pharmacology , Oligonucleotide Probes , Peritoneal Dialysis, Continuous Ambulatory , Peritoneum/immunology , Peritonitis/immunology , Peritonitis/metabolism , RNA, Messenger/analysis , Tetanus Toxoid/immunology
8.
Rev Med Interne ; 19(8): 542-7, 1998 Aug.
Article in French | MEDLINE | ID: mdl-9775069

ABSTRACT

INTRODUCTION: RS3PE syndrome (remittive symmetrical seronegative synovitis with pitting edema) was first described by MacCarthy in 1985. It is a rare type of seronegative polyarthritis occurring in the elderly. METHODS: Retrospective report of 13 cases (including eight male and five female patients; mean age 76.7 +/- 3.7 years) and search for previously reported cases, using the Medline database. RESULTS: Pitting edema was present at onset of disease in nine cases. Joint arthritis was bilateral, occurring in the wrist (13 cases), shoulder (six cases), elbow (six cases), knee (six cases), ankle (four cases), metacarpophalangeal (four cases) and hip (one case). Radiographies were normal. Mean erythrocyte sedimentation rate was 62 +/- 19 mm at the first hour and mean C-reactive protein level was 73 +/- 35 mg/L. Mild cholestasis was present in four of the seven patients for whom data were available. HLA B7 was present in five out of 12 cases (42%). Improvement was favorable, occurring over 7 months. Mean follow-up was 22.2 months. Fifty-nine other cases have been described in the literature. This syndrome, which affects the elderly, appears to be rare. Its clinical presentation is quite constant, with sudden onset, symmetrical polyarthritis and pitting edema. Its evolution, often long, is favorable. Rheumatoid arthritis and polymyalgia rheumatica are the main differential diagnoses. CONCLUSION: Due to its favorable outcome and the usefulness of a mild corticotherapy, this syndrome, though rare, should be diagnosed where necessary in elderly patients.


Subject(s)
Edema/diagnosis , Synovitis/diagnosis , Aged , Aged, 80 and over , Ankle Joint/physiopathology , Anti-Inflammatory Agents/therapeutic use , Arthritis/diagnosis , Arthritis, Rheumatoid/diagnosis , Blood Sedimentation , C-Reactive Protein/analysis , Cholestasis/complications , Diagnosis, Differential , Elbow Joint/physiopathology , Female , Follow-Up Studies , Glucocorticoids/therapeutic use , HLA-B7 Antigen/analysis , Hip Joint/physiopathology , Humans , Knee Joint/physiopathology , Male , Metacarpophalangeal Joint/physiopathology , Polymyalgia Rheumatica/diagnosis , Prednisone/therapeutic use , Prognosis , Retrospective Studies , Shoulder Joint/physiopathology , Wrist Joint/physiopathology
9.
AJR Am J Roentgenol ; 169(1): 63-7, 1997 Jul.
Article in English | MEDLINE | ID: mdl-9207502

ABSTRACT

OBJECTIVE: Our intent is to describe the role of CT in the intratumoral injection of Allovectin-7 (Vical, San Diego, CA), an allogeneic class I major histocompatibility complex antigen, HLA-B7, formulated with cationic lipid, in the treatment of metastatic malignant melanoma. MATERIALS AND METHODS: Ten patients with metastatic malignant melanoma were treated with gene therapy in which we used CT-guided intratumoral injection of plasmid DNA containing the HLA-B7 gene. This therapy was part of a phase I gene therapy trial in patients with metastatic melanoma. CT guidance was chosen as an accurate way to direct gene delivery in patients with deep, impalpable lesions. Tumor locations included pulmonary, mediastinal, hepatic, adrenal, and paracaval sites. Patients in the CT protocol underwent baseline CT studies. Examinations were repeated 2, 4, and 8 weeks after gene therapy and thereafter at 3-month intervals. Both injected and noninjected tumors were measured. CT-guided injections of 10, 50, or 250 micrograms of plasmid DNA were performed with 22-gauge spinal needles. Injection volumes were between 1.0 and 4.0 ml, depending on tumor size. CT-guided core biopsy specimens were obtained (with 18- or 20-gauge needles) from the selected tumor before therapy and 2, 4, and 8 weeks after therapy to assess HLA-B7 plasmid DNA and gene expression. Peripheral blood was analyzed for cytotoxic T lymphocytes directed against HLA-B7. RESULTS: CT-guided intratumoral injections were successful in delivering genetic material to all patients with impalpable tumors. Significant responses (as defined by a decrease of 25% or more in the product of the length and width of the injected tumor) were observed in six of the 10 patients. One of these six patients who had a solitary lesion remains free of disease 19 months after gene therapy. HLA-B7 protein expression was detected in 89% of biopsy specimens, and plasmid DNA and messenger RNA were detected in 56% and 22% of biopsy specimens, respectively. CONCLUSION: CT provides a safe, accurate, and efficacious way to monitor and assess tumor progression and response, and it provides guidance for biopsies and intratumoral injections during gene therapy. Significant responses in injected tumors of six of the 10 patients in our study suggest that further clinical trials of this gene therapy are warranted.


Subject(s)
DNA , Genetic Therapy , HLA-B7 Antigen/analysis , Lipids/administration & dosage , Melanoma/secondary , Melanoma/therapy , Plasmids/administration & dosage , Radiography, Interventional , Tomography, X-Ray Computed , Adult , Aged , DNA, Recombinant , Female , Humans , Injections, Intralesional , Lipids/therapeutic use , Liver Neoplasms/diagnostic imaging , Liver Neoplasms/immunology , Liver Neoplasms/secondary , Liver Neoplasms/therapy , Lung Neoplasms/diagnostic imaging , Lung Neoplasms/immunology , Lung Neoplasms/secondary , Lung Neoplasms/therapy , Lymphatic Metastasis , Male , Melanoma/diagnostic imaging , Melanoma/immunology , Middle Aged , Plasmids/therapeutic use
10.
Rev Invest Clin ; 49(3): 183-7, 1997.
Article in Spanish | MEDLINE | ID: mdl-9380972

ABSTRACT

AIM: To study the HLA markers in Mexican couples who have suffered three or more spontaneous abortions. DESIGN: The study included 24 couples with recurrent abortions and 32 with normal fertility. METHOD: HLA class I (A, B, C) and class II (DR, DQ) typing was done with a standard microlymphocytoxity test. The intergroup differences were evaluated by chi-square and the Fisher exact test. RESULTS: The frequency of the MHC markers in the males and females of couples with abortions were not significantly different from those in fertile couples. However, the abortion couples shared class I antigens more often than expected from random mating as compared to fertile couples, specially in the HLA-B locus. We also found a significantly decreased frequency of the HLA-B7 antigen in males belonging to the abortion group. CONCLUSION: These results suggest that HLA-B antigens may be markers for genes related to pregnancy outcome in Mexicans.


Subject(s)
Abortion, Habitual/immunology , HLA Antigens/analysis , Abortion, Habitual/epidemiology , Abortion, Habitual/genetics , Adult , Disease Susceptibility , Female , Fertility/genetics , Fertility/immunology , Gene Frequency , HLA Antigens/genetics , HLA-B7 Antigen/analysis , Histocompatibility Testing , Humans , Male , Mexico/epidemiology , Pregnancy , Pregnancy Outcome
11.
Ophthalmologica ; 211(4): 266-7, 1997.
Article in English | MEDLINE | ID: mdl-9216021

ABSTRACT

In this work we describe a case of papillophlebitis type II according to Hayreh in a young woman affected by psoriatic arthritis. On the basis of an analysis of the patient's HLA system--B7, DR7 (characteristics of psoriatic arthritis) and B51 (present in 81% of patients affected by Behçet's syndrome)--we hypothesize that this may be a case of an 'overlap syndrome'. In rheumatology, this term usually refers to the presence in a single patient of characteristic features of two or more diseases. In fact, papillophlebitis is a complication which has never been described in psoriatic arthritis, while, in Behçet's syndrome, retinal vasculitis is well known.


Subject(s)
Arthritis, Psoriatic/complications , Retinal Vessels , Vasculitis/complications , Adult , Anti-Inflammatory Agents/therapeutic use , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Arthritis, Psoriatic/drug therapy , Arthritis, Psoriatic/immunology , Female , Gold/therapeutic use , HLA-B7 Antigen/analysis , HLA-DR7 Antigen/analysis , Humans , Indomethacin/therapeutic use , Prednisolone/therapeutic use , Syndrome , Vasculitis/drug therapy , Vasculitis/immunology
12.
Allerg Immunol (Paris) ; 29(1): 11-4, 1997 Jan.
Article in French | MEDLINE | ID: mdl-9213414

ABSTRACT

Among HLA-associated diseases, the strong association between HLA B27 and ankylosing spondylitis (AS) allows to perform HLA B27 typing for the diagnosis of this disease. The technique described: double immunostaining anti-HLA B7/HLA B27 on whole blood samples and analysis by flow cytometry is a rapid method for the detection of HLA B27 antigen. We have compared the results obtained with those of the TERASAKI microlymphocytotoxicity reference method on a population of 300 patients. The absence of false negative results indicates that this test is suitable for AS screening. The use of two monoclonal antibodies proves to be effective in eliminating cross reactions described with HLA B7 flow cytometric techniques using single monoclonal antibody. This technique allows to restrict the use of microlymphocy-totoxicity to patients presenting with both HLA B7 and B27 positive reactivities.


Subject(s)
Flow Cytometry/methods , HLA-B27 Antigen/analysis , HLA-B7 Antigen/analysis , Histocompatibility Testing/methods , Immunophenotyping/methods , Antibodies, Monoclonal/immunology , Antibody Specificity , Antilymphocyte Serum/immunology , Female , Humans , Male , Predictive Value of Tests , Spondylitis, Ankylosing/immunology
13.
Br J Dermatol ; 135(1): 36-41, 1996 Jul.
Article in English | MEDLINE | ID: mdl-8776356

ABSTRACT

We have examined the clinicopathological correlates of 74 patients with histologically confirmed Langerhans cell histiocytosis. Factors that influenced disease outcome included, three or more organ/systems being involved, a disease onset before the age of 2 years, the involvement of certain vital organs/systems such as liver/spleen, bone marrow and lungs, and male gender. The total number of involved organs/systems was the single most important determinant of disease outcome. Mortality rate in patients with three or more organs/systems involved, was 26%, as compared with 0% in the group with one or two organs/systems involved (chi 2 = 11.2, P = 0.008). There were no familial cases in our series, but we looked for a possible immunogenetic association by tissue typing 46 Caucasian sufferers and comparing the results with 117 controls. We used normal peripheral blood lymphocytes in 39 cases, Epstein-Barr virus-transformed lymphoblastoid cell lines in 12 cases, and both peripheral blood and Epstein-Barr virus-transformed lymphocytes in five cases. The HLA-B7 antigen was significantly increased Langerhans cell histiocytosis patients (19 of 46 = 41.3%) compared with 19 of 117 (16.2%) in the control group chi 2 = 11.2, relative risk = 3.6, P value after correction = 0.013). Attempt to stratify the disease into single-system or multisystem disease did not result in any significant association.


Subject(s)
HLA Antigens/analysis , Histiocytosis, Langerhans-Cell/immunology , Histiocytosis, Langerhans-Cell/pathology , Adolescent , Adult , Age Factors , Cell Transformation, Viral , Child , Child, Preschool , Female , HLA-B7 Antigen/analysis , Histocompatibility Testing , Humans , Infant , Male , Middle Aged , Prognosis , Sex Factors
14.
Blood Cells Mol Dis ; 22(3): 195-204, 1996.
Article in English | MEDLINE | ID: mdl-9075570

ABSTRACT

We postulated that the severity of iron overload in homozygous hemochromatosis probands is related to the expression of HLA-A3 or D6S105 allele 8. Therefore, we used these markers to characterize Alabama hemochromatosis probands and normal control subjects. We then quantified the blood removed by phlebotomy to exhaust body iron stores and maintain normal serum ferritin concentrations in our hemochromatosis probands. Induction and maintenance phlebotomy requirements were significantly greater in presumed HLA-A3 homozygotes or in D6S105 allele 8 homozygotes than in homozygous probands lacking these markers. Intermediate values were observed in probands who were HLA-A3 or allele 8 heterozygotes, respectively. We also analyzed data from males and females separately. Among subjects of the same sex, the induction and maintenance phlebotomy requirements in subjects presumed to be HLA-A3 homozygotes or in allele 8 homozygotes were greater than those of other groups. Our results support the hypothesis that the severity of iron overload in hemochromatosis is determined predominantly by genetic factors, and provide evidence that two or more mutations for hemochromatosis exist. However, the design of our study does not permit a distinction to be made between allelic and locus heterogeneity for the hemochromatosis gene(s).


Subject(s)
Hemochromatosis/genetics , Alleles , Female , Genetic Markers , HLA-A3 Antigen/analysis , HLA-B Antigens/analysis , HLA-B14 Antigen , HLA-B7 Antigen/analysis , Humans , Male , Phenotype , Phlebotomy
15.
Fertil Steril ; 64(5): 909-16, 1995 Nov.
Article in English | MEDLINE | ID: mdl-7589633

ABSTRACT

OBJECTIVE: To evaluate whether the expression of human leukocyte antigen (HLA) class I on eutopic and ectopic endometrial cells modify the susceptibility to lysis mediated by lymphocytes. DESIGN: Evaluation of T lymphocyte cytotoxic activity and HLA class I expression on endometrial cells. SETTING: Subjects were recruited at laparoscopy. PATIENTS: Patients with endometriosis (n = 7). Healthy women as controls (n = 10). MAIN OUTCOME MEASURES: Human leukocyte antigen class I molecule analysis of endometrial cells was carried out by immunofluorescence and flow cytometry. Phenotyping of T lymphocytes was performed to analyze T-cell subsets. Cytotoxicity was performed to determine cytolytic activity against endometrial cells. RESULTS: In vitro culture of endometrial cells down-regulates the expression of HLA class I molecules and enhances the susceptibility to lysis mediated by natural killer (NK)-like T lymphocytes. Cytolytic T-cell clones, expressing the CD94 antigen, are inhibited by the HLA-B7 allele on endometrial cells. Ectopic endometrial cells modulate the expression of HLA class I molecules. CONCLUSIONS: The resistance to lysis of endometrial cells is related to expression of surface HLA class I molecules, which send a negative signal for lysis mediated by NK-like T lymphocytes. The HLA-B7 allele inhibits the cytotoxic activity, suggesting that the growth of ectopic endometrial cells might be under a genetic control.


Subject(s)
Endometriosis/genetics , Endometriosis/physiopathology , Histocompatibility Antigens Class I/physiology , Killer Cells, Natural/physiology , Alleles , Cells, Cultured , Down-Regulation , Endometriosis/etiology , Endometrium/chemistry , Endometrium/metabolism , Endometrium/pathology , Female , Flow Cytometry , Fluorescent Antibody Technique, Indirect , Gene Expression Regulation , Genes, MHC Class I , HLA-B7 Antigen/analysis , HLA-B7 Antigen/genetics , Histocompatibility Antigens Class I/biosynthesis , Histocompatibility Antigens Class I/genetics , Humans , Interferon-gamma/pharmacology , Killer Cells, Natural/immunology , Killer Cells, Natural/pathology , Phenotype , T-Lymphocytes, Cytotoxic/pathology , T-Lymphocytes, Cytotoxic/physiology
16.
Ann Rheum Dis ; 54(8): 681-4, 1995 Aug.
Article in English | MEDLINE | ID: mdl-7677447

ABSTRACT

OBJECTIVE: To evaluate the outcome of patients with remitting seronegative symmetrical synovitis with pitting oedema (RS3PE). METHODS: In a retrospective chart review study, we identified all the patients presenting with polyarthritis and pitting oedema in the past 20 years. We tried to recall the 24 patients with characteristics of RS3PE according to McCarty et al. Two patients had died and four could not be traced. Five could not be seen after the initial period of follow up; relevant data were obtained from their practitioner. For the remaining 13 patients, clinical, radiological, and biological evaluation was performed in our department, with the last assessment in 1993. RESULTS: The follow up period was from one to 18 years (mean 4.6 (SD 4.5) years). Eleven patients developed one or several recurrences of articular manifestations consisting of mild oligoarthritis (n = 8), definite spondyloarthropathy (n = 2), and rheumatoid arthritis (n = 1). The delay of the first recurrence was 18 months to 12 years after the first attack. Thirteen patients had no recurrence, but three of them developed remarkable features: rheumatoid factor, antinuclear antibodies (1/2000), Sjögren's syndrome. HLA B typing was performed in nine patients and revealed B7 (n = 2), B27 (n = 2) and B22 (n = 2). Isolated HLA B27 typing was performed in two other patients and was positive in one. CONCLUSION: The long term outcome of RS3PE can lead to different rheumatic diseases. RS3PE appears to be a syndrome related to the elderly onset of the rheumatic diseases, including spondyloarthropathy and rheumatoid arthritis, rather than a specific entity.


Subject(s)
Arthritis/complications , Edema/etiology , Synovitis/etiology , Aged , Aged, 80 and over , Arthritis, Rheumatoid/complications , Female , Follow-Up Studies , HLA-B27 Antigen/analysis , HLA-B35 Antigen/analysis , HLA-B7 Antigen/analysis , Histocompatibility Testing , Humans , Male , Middle Aged , Recurrence , Retrospective Studies , Spinal Diseases/complications , Syndrome
17.
Am J Ophthalmol ; 119(5): 660-2, 1995 May.
Article in English | MEDLINE | ID: mdl-7733198

ABSTRACT

PURPOSE/METHODS: To test the hypothesis that there may be inherited predisposition in acute multifocal placoid pigment epitheliopathy, HLA typing was undertaken in two cousins with recurrent disease. RESULTS/CONCLUSIONS: Both cousins were shown to have HLA antigens DR2 but not B7; both antigens have been associated with this disorder previously. This finding is compatible with the concept that DR2 may be associated with an increased risk of recurrent disease.


Subject(s)
Retinal Diseases/genetics , Acute Disease , Adult , Female , HLA-B7 Antigen/analysis , HLA-DR2 Antigen/analysis , Humans , Male , Pedigree , Pigment Epithelium of Eye/immunology , Recurrence , Retinal Diseases/immunology
18.
Hum Gene Ther ; 6(5): 575-90, 1995 May.
Article in English | MEDLINE | ID: mdl-7578395

ABSTRACT

To evaluate the safety of a plasmid DNA-lipid complex, a series of good laboratory practice (GLP) safety studies were conducted with VCL-1005, a plasmid DNA expression vector containing both the human class I MHC HLA-B7 heavy-chain and the beta 2-microglobulin (beta 2m) light-chain genes formulated with the cationic lipid, DMRIE/DOPE. In mice, the repeated intravenous injection of VCL-1005 at plasmid DNA doses of 0.1, 1.0, or 10 micrograms for 14 days had only incidental effects on clinical chemistry and hematology, and did not result in any organ pathology. Repeated intrahepatic injections of VCL-1005 in mice did not result in significant liver histopathology or significant alterations in liver enzymes. In cynomolgus monkeys, the repeated intravenous administration of VCL-1005 at a cumulative dose of 720 micrograms of DNA had no effects on clinical chemistry, hematology, or organ pathology. Thus, systemic administration of a plasmid DNA expression vector containing the coding sequence for a foreign MHC class I molecule did not result in significant toxicity or a pathological immune response in animals. These results suggest that the direct transfer of VCL-1005, a plasmid DNA-lipid complex, could be used for the safe in vivo delivery of recombinant DNA for a cancer gene therapy trial.


Subject(s)
DNA , Gene Transfer Techniques , Genetic Therapy , HLA-B7 Antigen/genetics , Lipids/toxicity , Neoplasms/therapy , Plasmids/administration & dosage , Plasmids/toxicity , Animals , Blood Chemical Analysis , DNA, Recombinant/administration & dosage , Female , Genetic Therapy/adverse effects , HLA-B7 Antigen/analysis , Humans , Injections , Lipids/administration & dosage , Liver/drug effects , Liver/immunology , Liver/pathology , Macaca fascicularis , Male , Mice , Mice, Inbred BALB C , beta 2-Microglobulin/genetics
19.
J Neurol ; 242(3): 174-7, 1995 Feb.
Article in English | MEDLINE | ID: mdl-7751862

ABSTRACT

Ten patients with clinically isolated idiopathic retinal vasculitis who had a positive family history for multiple sclerosis (MS) or positive typing for HLA B7 underwent magnetic resonance imaging (MRI) of brain and optic nerves in order to establish the frequency of clinically silent lesions. Brain MRI was normal in seven and abnormal in three: one had a single small white matter lesion, two had extensive white matter abnormalities resembling those seen in MS. In two patients a lesion was shown in the optic nerve. These findings suggest that a minority of patients with idiopathic retinal vasculitis have disseminated central nervous system lesions characteristic of MS, the frequency of such changes being less than in patients with isolated optic neuritis.


Subject(s)
Brain/pathology , Magnetic Resonance Imaging , Retinal Diseases/diagnosis , Vasculitis/diagnosis , Adolescent , Adult , Female , Fluorescein Angiography , HLA-B7 Antigen/analysis , Humans , Male , Medical Records , Multiple Sclerosis/genetics , Optic Nerve/pathology
20.
Hum Immunol ; 40(3): 235-46, 1994 Jul.
Article in English | MEDLINE | ID: mdl-7960968

ABSTRACT

A soluble, secreted form of HLA-B7 was engineered by replacing the exons encoding the transmembrane and cytoplasmic domains of the B7 gene with a CI. The modified gene, gsB7, transfected into J27.2 or C1R cell lines, produced a secreted protein, sB7, serologically recognized as B7. Size fractionation showed one species of sB7 at the approximately 55 kD expected for an sB7 alpha-chain-beta 2m heteroduplex, and another at approximately 120 kD which had the same constituent chains and was a dimer of the 55-kD species. Dimer formation appeared to be related to protein concentration but not to disulfide bridging. The sB7 heavy chain on SDS-PAGE showed a doublet at approximately 39 and approximately 42 kD; enzyme analysis indicated that the two bands differed only by a carboxyl terminal polypeptide. Analysis of gsB7 transfectants' mRNA by Northern blots and PCR revealed message fully spliced or with retained CI, accounting for the 39- and 42-kD bands, respectively, and apparently untranslated message with I3 retained. sB7 was not detectable on the surface of gsB7 transfectants by CTLs, nor did it inhibit those CTLs. Production of the sB7 protein provides a ready, consistent source of soluble class I antigen for further study, including test materials for tolerogenicity studies in animal models.


Subject(s)
HLA-B7 Antigen/genetics , Amino Acid Sequence , Cell Line , Cells, Cultured , Cytotoxicity Tests, Immunologic , Electrophoresis, Polyacrylamide Gel , Gene Expression , Genes, MHC Class I/genetics , Genetic Engineering , HLA-B7 Antigen/analysis , HLA-B7 Antigen/isolation & purification , Humans , Molecular Sequence Data , Molecular Weight , Polymers , RNA, Messenger/analysis , Recombinant Proteins/analysis , Recombinant Proteins/isolation & purification , Solubility , Transfection
SELECTION OF CITATIONS
SEARCH DETAIL
...